Study guide

10.1 Epidemiological Measures of Disease Frequency & Association

AHIMA Certified Health Data Analyst CHDA

Track your progress as you read

Finished sections get a check mark.

1 Introduction & CHDA Exam Overview

0.1 About the AHIMA CHDA Exam 0.2 How to Use This Study Guide

2 Chapter 1: Healthcare Delivery Systems & Revenue Cycle

1.1 Healthcare Delivery Settings & Organizational Structures 1.2 Healthcare Revenue Cycle Management & Reimbursement Models 1.3 Regulatory Reporting & Accreditation Agencies

3 Chapter 2: Health Informatics, Datasets & AI

2.1 Electronic Health Records (EHR) & Health Informatics Foundations 2.2 Healthcare Datasets, Benchmarks & Population Health 2.3 Analytics Hierarchy & Artificial Intelligence in Healthcare

4 Chapter 3: Clinical Terminologies, Classifications & Standards

3.1 Clinical Classification Systems: ICD-10-CM/PCS & CPT/HCPCS 3.2 Clinical Terminologies & Ontologies: SNOMED CT, LOINC & RxNorm 3.3 Interoperability & Data Exchange Standards: HL7 v2, CDA & FHIR

5 Chapter 4: Business Needs Assessment & Scoping

4.1 Stakeholder Engagement & Analytics Needs Elicitation 4.2 Defining Metrics, KPIs & Healthcare Value 4.3 Analytics Project Management & Analysis Planning

6 Chapter 5: Data Sourcing, Lineage & Collection Methods

5.1 Healthcare Data Sourcing & Lineage 5.2 Healthcare Data Collection Methods & Architectures 5.3 Clinical & Financial Data Extraction

7 Chapter 6: Data Cleansing, Transformation & Validation

6.1 Healthcare Data Quality Assessment 6.2 Data Cleansing & Anomaly Remediation 6.3 Data Transformation, Mapping & Validation

8 Chapter 7: Exploratory Data Analysis & Descriptive Statistics

7.1 Healthcare Data Types & Scales of Measurement 7.2 Measures of Central Tendency & Dispersion 7.3 Exploratory Data Analysis in Clinical Populations

9 Chapter 8: Inferential Statistics & Hypothesis Testing

8.1 Sampling Techniques & Probability in Healthcare 8.2 Hypothesis Testing Fundamentals 8.3 Parametric vs. Non-Parametric Tests

10 Chapter 9: Advanced Statistical Modeling & Risk Adjustment

9.1 Correlation & Regression Analysis 9.2 Risk Adjustment & Healthcare Severity Modeling 9.3 Survival Analysis & Model Evaluation

11 Chapter 10: Healthcare Epidemiology & Study Methodologies

10.1 Epidemiological Measures of Disease Frequency & Association 10.2 Healthcare Study Designs & Methodologies 10.3 Confounding, Bias & Health Equity Analytics

12 Chapter 11: Healthcare Data Visualization & Dashboard Design

11.1 Principles of Effective Healthcare Data Visualization 11.2 Selecting Appropriate Healthcare Visualizations 11.3 Executive & Clinical Dashboard Architecture

13 Chapter 12: Healthcare Performance Measurement & CMS Quality Programs

12.1 CMS Quality Programs & Value-Based Purchasing 12.2 Clinical Quality Measures & Benchmarking 12.3 Financial Analytics & Case Mix Index Analysis

14 Chapter 13: Communicating Insights & Narrative Analytics

13.1 Translating Complex Analytics for Diverse Audiences 13.2 Contextualizing Limitations, Assumptions & Uncertainty 13.3 Narrative Reporting & Data-Driven Decision Support

15 Chapter 14: Healthcare Data Governance Frameworks & Stewardship

14.1 Enterprise Data Governance Frameworks 14.2 Data Stewardship & Master Patient Index (MPI) Management 14.3 Metadata Management & Business Glossaries

16 Chapter 15: Healthcare Privacy, Security & Data Ethics

15.1 HIPAA Privacy & Security Rules for Analysts 15.2 De-Identification Methodologies 15.3 Data Ethics, Audit Trails & Secondary Data Use

10.1 Epidemiological Measures of Disease Frequency & Association

Key Takeaways Explain This Topic AI

Prevalence measures existing disease burden in a population at a specific point or period ( P = Existing Cases / Total Population at Risk P = \text{Existing Cases} / \text{Total Population at Risk} P = Existing Cases / Total Population at Risk ), whereas Incidence captures new disease onset over time (Cumulative Incidence as risk, and Incidence Rate as density using person-time at risk).

Under steady-state dynamic equilibrium, disease prevalence is approximately the product of incidence rate and mean disease duration ( P ≈ I × D ˉ P \approx I \times \bar{D} P ≈ I × D ˉ ); medical therapies that prolong survival increase prevalence even when incidence remains constant.

Healthcare mortality and morbidity metrics—including Crude Mortality, Cause-Specific Mortality, Case Fatality Rate ( C F R = Deaths from Disease / Diagnosed Cases CFR = \text{Deaths from Disease} / \text{Diagnosed Cases} CFR = Deaths from Disease / Diagnosed Cases ), Maternal/Infant Mortality, and the Standardized Infection Ratio ( SIR = Observed / Predicted \text{SIR} = \text{Observed} / \text{Predicted} SIR = Observed / Predicted )—provide standardized benchmarks for population health and hospital quality.

Relative Risk ( R R = I e / I u RR = I_e / I_u RR = I e ​ / I u ​ ) evaluates relative strength of association in prospective cohort studies and clinical trials, while Odds Ratio ( O R = a d / b c OR = ad / bc OR = a d / b c ) evaluates exposure-disease odds in case-control studies; under the Rare Disease Assumption, O R ≈ R R OR \approx RR OR ≈ RR .

Attributable Risk ( A R = I e − I u AR = I_e - I_u A R = I e ​ − I u ​ ), Attributable Risk Percent ( A R % AR\% A R % ), Number Needed to Treat ( N N T = 1 / A R R NNT = 1 / ARR NNT = 1/ A RR ), and Number Needed to Harm ( N N H = 1 / A R I NNH = 1 / ARI NN H = 1/ A R I ) quantify absolute clinical impact and guide healthcare resource allocation decisions.

Last updated: August 2026

Epidemiological Measures of Disease Frequency & Association

Epidemiology forms the quantitative and scientific cornerstone of population health management, clinical quality improvement, disease surveillance, and evidence-based clinical decision support. For the Certified Health Data Analyst (CHDA), mastering epidemiological measures allows the translation of raw transactional electronic health record (EHR) data, claims databases, and infection surveillance registries into actionable insights regarding disease burden, etiology, treatment efficacy, and patient safety. Whether calculating standardized infection ratios for hospital-acquired condition penalties, modeling the community-level prevalence of chronic conditions, or interpreting relative risk reductions in clinical trial literature, analysts must possess an uncompromising command of both frequency metrics and comparative measures of association.

1. Measures of Disease Frequency: Prevalence vs. Incidence

Quantifying disease occurrence requires defining the population at risk, the temporal window of observation, and the distinction between existing versus newly developed clinical conditions. +---------------------------------------------------------------------------------------------------+

  • | DISEASE FREQUENCY METRIC TAXONOMY |
  • +-------------------------------------------------+-------------------------------------------------+
  • | PREVALENCE (Existing Disease Burden) | INCIDENCE (New Disease Onset) |
  • | - Measures state of being diseased | - Measures transition from healthy to diseased |
  • | - Numerator: ALL existing active cases | - Numerator: ONLY NEW incident cases |
  • | - Denominator: Total population at risk | - Denominator: Population initially disease-free|
  • | - Types: Point Prevalence vs. Period Prevalence | - Types: Cumulative Incidence vs. Incidence Rate|
  • +-------------------------------------------------+-------------------------------------------------+
  • │ ▲
  • │ Dynamic Equilibrium ($P \approx I \times \bar{D}$)│
  • ▼ │
  • [Incidence Inflow] ─────────────── [Disease Duration / Cure / Mortality]
  • Prevalence: Point vs. Period Prevalence

Prevalence measures the proportion of individuals within a defined population who have a specified disease, condition, or characteristic at a specific point or period in time. Because prevalence is a proportion (ranging from 0 to 1, or 0% to 100%), it possesses no units of time in its denominator. Prevalence ( P ) = Number of existing cases of disease at a specified time Total population at risk at that specified time \text{Prevalence } (P) = \frac{\text{Number of existing cases of disease at a specified time}}{\text{Total population at risk at that specified time}} Prevalence ( P ) = Total population at risk at that specified time Number of existing cases of disease at a specified time ​

Point Prevalence: Assesses the disease burden at a single, exact cross-sectional calendar date or clinical encounter point (e.g., the proportion of hospitalized patients in a medical center with an active Clostridioides difficile infection on July 1 at 08:00 AM).

Period Prevalence: Assesses the total number of individuals who had the disease at any point during an extended observation interval (e.g., calendar year 2025). The numerator includes both pre-existing cases present at the start of the period and new incident cases that developed during the period; the denominator is typically the mid-period population at risk.

Cumulative Lifetime Prevalence: The proportion of individuals in a population who have ever experienced the clinical condition at any point up to the survey date (e.g., lifetime prevalence of major depressive disorder).

Incidence: Cumulative Incidence vs. Incidence Rate (Density)

Incidence measures the rate of flow or transition from a healthy, disease-free state to the development of disease among individuals at risk. Individuals who already have the condition at baseline are strictly excluded from the denominator.

1. Cumulative Incidence ( C I CI C I ) / Incidence Proportion (Risk)

Cumulative incidence represents the average individual probability or mathematical risk of developing a clinical disease over a specified, fixed time window. C I = Number of new incident cases occurring during the specified time period Number of disease-free individuals at risk at the beginning of the period CI = \frac{\text{Number of new incident cases occurring during the specified time period}}{\text{Number of disease-free individuals at risk at the beginning of the period}} C I = Number of disease-free individuals at risk at the beginning of the period Number of new incident cases occurring during the specified time period ​

Assumptions and Use Case: Assumes a closed cohort where all individuals are followed for the entirety of the study duration without major loss to follow-up, competing mortality, or staggered enrollment. C I CI C I ranges from 0 to 1 and must always be paired with an explicit time window (e.g., "a 5-year cumulative incidence of myocardial infarction of 8%").

2. Incidence Rate ( I R IR I R ) / Incidence Density

In real-world healthcare analytics, open and dynamic cohorts exhibit variable follow-up durations, loss to follow-up, migration, and staggered patient enrollment. The Incidence Rate handles variable observation windows by utilizing person-time at risk in the denominator. I R = Number of new incident cases occurring during the specified time period Total person-time at risk accrued across the cohort IR = \frac{\text{Number of new incident cases occurring during the specified time period}}{\text{Total person-time at risk accrued across the cohort}} I R = Total person-time at risk accrued across the cohort Number of new incident cases occurring during the specified time period ​

Person-Time Calculation: Person-time is the sum of time intervals contributed by each individual subject while disease-free and under active observation. Common units include person-years , person-months , or 1,000 patient-days .

Handling Censoring: When a subject develops the outcome, dies from a competing cause, or is lost to follow-up, they immediately cease contributing person-time at risk.

Mathematical Relationship: Dynamic Equilibrium ( P ≈ I × D ˉ P \approx I \times \bar{D} P ≈ I × D ˉ )

When a clinical condition and population are in a steady state—meaning immigration, emigration, overall incidence, and disease resolution rates remain stable over time—prevalence, incidence rate ( I I I ), and average disease duration ( D ˉ \bar{D} D ˉ ) are mathematically coupled: P ≈ I × D ˉ ⟺ P 1 − P = I × D ˉ P \approx I \times \bar{D} \quad \Longleftrightarrow \quad \frac{P}{1 - P} = I \times \bar{D} P ≈ I × D ˉ ⟺ 1 − P P ​ = I × D ˉ

Where:

  • P P P = Point prevalence (expressed as a proportion)
  • I I I = Incidence rate (per unit time)
  • D ˉ \bar{D} D ˉ = Mean duration of disease (in the identical unit of time)
  • Clinical Implications for Healthcare Data Analysts

Therapeutic Breakthroughs: A medical breakthrough that improves survival for a chronic fatal disease (e.g., antiretroviral therapy for HIV or insulin for Type 1 Diabetes) prolongs disease duration D ˉ \bar{D} D ˉ . Consequently, prevalence increases , even if prevention programs keep incidence I I I constant or decreasing.

Rapid Cures vs. Fatal Conditions: Diseases with short duration (due to rapid curative treatment, such as uncomplicated community-acquired pneumonia, or high case fatality, such as acute hemorrhagic stroke) exhibit low prevalence , even when the annual incidence rate I I I is high. +---------------------------------------------------------------------------------------------------+

  • | DYNAMIC EQUILIBRIUM OF DISEASE OCCURRENCE |
  • +---------------------------------------------------------------------------------------------------+
  • │
  • [ NEW INCIDENT CASES (Incidence Rate: I) ]
  • │ (Inflow)
  • ▼
  • ┌───────────────────────────────────────────────────────────┐
  • │ PREVALENCE POOL ($P$) │
  • │ Existing Active Cases │
  • │ $P \approx I \times \bar{D}$ │
  • └───────────────────────────────────────────────────────────┘
  • │ (Outflow) │ (Outflow)
  • ▼ ▼
  • [ RECOVERY / CURE ] [ MORTALITY / DEATH ]
  • (Decreases Duration $\bar{D}$) (Decreases Duration $\bar{D}$)
  • 2. Healthcare Mortality and Morbidity Metrics

Health data analysts routinely calculate vital statistics, population-level mortality benchmarks, and hospital-acquired condition rates to assess healthcare system performance and community health needs.

Metric Mathematical Formula Standard Multiplier Clinical / Analytic Definition

Crude Mortality Rate Total deaths from all causes in calendar year Total estimated mid-year population \frac{\text{Total deaths from all causes in calendar year}}{\text{Total estimated mid-year population}} Total estimated mid-year population Total deaths from all causes in calendar year ​ × 1 , 000 \times 1,000 × 1 , 000 or 100 , 000 100,000 100 , 000 Overall mortality risk unadjusted for age, sex, or clinical risk structure.

Cause-Specific Mortality Rate Deaths attributable to specific diagnosis in year Total estimated mid-year population \frac{\text{Deaths attributable to specific diagnosis in year}}{\text{Total estimated mid-year population}} Total estimated mid-year population Deaths attributable to specific diagnosis in year ​ × 100 , 000 \times 100,000 × 100 , 000 Population-level risk of dying from a designated disease (e.g., Stroke mortality).

Case Fatality Rate (CFR) Deaths attributable to specific disease Total confirmed/diagnosed cases of that disease \frac{\text{Deaths attributable to specific disease}}{\text{Total confirmed/diagnosed cases of that disease}} Total confirmed/diagnosed cases of that disease Deaths attributable to specific disease ​ × 100 % \times 100\% × 100% Proportion of diagnosed individuals who die from the condition; measures severity/lethality.

Maternal Mortality Ratio Maternal deaths due to pregnancy-related causes Total documented live births \frac{\text{Maternal deaths due to pregnancy-related causes}}{\text{Total documented live births}} Total documented live births Maternal deaths due to pregnancy-related causes ​ × 100 , 000 \times 100,000 × 100 , 000 Obstetric safety indicator measuring pregnancy-related deaths per 100k live births.

Infant Mortality Rate (IMR) Deaths of infants aged < 1 year Total live births in same calendar year \frac{\text{Deaths of infants aged } < 1 \text{ year}}{\text{Total live births in same calendar year}} Total live births in same calendar year Deaths of infants aged < 1 year ​ × 1 , 000 \times 1,000 × 1 , 000 Core global indicator of population health, maternal nutrition, and pediatric access.

Neonatal Mortality Rate Deaths of infants aged < 28 days Total live births in same calendar year \frac{\text{Deaths of infants aged } < 28 \text{ days}}{\text{Total live births in same calendar year}} Total live births in same calendar year Deaths of infants aged < 28 days ​ × 1 , 000 \times 1,000 × 1 , 000 Captures prenatal, congenital, and intrapartum obstetric/neonatal clinical complications.

Post-Neonatal Mortality Rate Deaths of infants aged 28 days to < 1 year Total live births in same calendar year \frac{\text{Deaths of infants aged } 28 \text{ days to } < 1 \text{ year}}{\text{Total live births in same calendar year}} Total live births in same calendar year Deaths of infants aged 28 days to < 1 year ​ × 1 , 000 \times 1,000 × 1 , 000 Reflects infectious diseases, environmental exposures, and pediatric social determinants.

Critical Distinction: Cause-Specific Mortality Rate vs. Case Fatality Rate

A frequent area of confusion on certification exams is distinguishing between Cause-Specific Mortality and Case Fatality Rate:

Cause-Specific Mortality Rate: Denominator is the entire general population (diseased and non-diseased alike). It answers: What is the risk of a person in the general community dying from this disease?

Case Fatality Rate (CFR): Denominator is strictly individuals who have been diagnosed with the disease . It answers: Given that a patient is diagnosed with this disease, what is the probability they will die from it?

Hospital-Acquired Infection (HAI) Metrics & The Standardized Infection Ratio (SIR)

Healthcare systems report healthcare-associated infections to the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN), including:

  • Central Line-Associated Bloodstream Infections (CLABSI)
  • Catheter-Associated Urinary Tract Infections (CAUTI)
  • Surgical Site Infections (SSI)
  • Ventilator-Associated Events / Pneumonia (VAE/VAP)

Device-Associated Infection Rate Formula: Device-Associated Rate = Number of Device-Associated HAIs Total Device-Days (e.g., Central Line Days) × 1 , 000 \text{Device-Associated Rate} = \frac{\text{Number of Device-Associated HAIs}}{\text{Total Device-Days (e.g., Central Line Days)}} \times 1,000 Device-Associated Rate = Total Device-Days (e.g., Central Line Days) Number of Device-Associated HAIs ​ × 1 , 000

Standardized Infection Ratio (SIR):

The SIR is an indirect standardization metric utilized by CMS in the Hospital Inpatient Quality Reporting (IQR) and Hospital-Acquired Condition (HAC) Reduction programs to benchmark hospital safety against national baselines: Standardized Infection Ratio (SIR) = Observed ( O ) Number of HAIs Predicted ( P ) Number of HAIs \text{Standardized Infection Ratio (SIR)} = \frac{\text{Observed } (O) \text{ Number of HAIs}}{\text{Predicted } (P) \text{ Number of HAIs}} Standardized Infection Ratio (SIR) = Predicted ( P ) Number of HAIs Observed ( O ) Number of HAIs ​

Predicted Number ( P P P ): Derived from multivariate multivariable negative binomial regression models established by the CDC, adjusting for hospital bed size, intensive care unit type, teaching hospital status, medical school affiliation, and patient-level clinical comorbidities.

Interpretation:

SIR = 1.0 \text{SIR} = 1.0 SIR = 1.0 : Observed infection count exactly matches national risk-adjusted baseline expectations.

SIR < 1.0 \text{SIR} < 1.0 SIR < 1.0 : Statistically fewer infections observed than predicted (superior clinical performance).

SIR > 1.0 \text{SIR} > 1.0 SIR > 1.0 : Significantly excess infections observed compared to risk-adjusted benchmarks (potential penalty under CMS HAC reduction program).

3. Measures of Association: 2x2 Contingency Table Analytics

Epidemiological measures of association quantify the relationship between an exposure (risk factor, pharmaceutical agent, surgical technique) and a health outcome (disease, complication, mortality, 30-day readmission). All primary measures are computed from the canonical 2 × 2 2 \times 2 2 × 2 Contingency Table . +---------------------------------------------------------------------------------------------------+

  • | THE STANDARD 2x2 CONTINGENCY TABLE |
  • +-----------------------------+-----------------------------+---------------------------------------+
  • | | OUTCOME POSITIVE ($D^+$) | OUTCOME NEGATIVE ($D^-$) | TOTAL |
  • +-----------------------------+-----------------------------+---------------------------------------+
  • | EXPOSED ($E^+$) | a (Exposed with Disease) | b (Exposed without Disease) | a + b |
  • | UNEXPOSED ($E^-$) | c (Unexposed with Disease) | d (Unexposed without Disease) | c + d |
  • +-----------------------------+-----------------------------+---------------------------------------+
  • | TOTAL | a + c | b + d | N |
  • +-----------------------------+-----------------------------+---------------------------------------+
  • Incidence / Risk in Exposed ( I e I_e I e ​ ): I e = a a + b I_e = \frac{a}{a + b} I e ​ = a + b a ​
  • Incidence / Risk in Unexposed ( I u I_u I u ​ ): I u = c c + d I_u = \frac{c}{c + d} I u ​ = c + d c ​
  • 1. Relative Risk / Risk Ratio ( R R RR RR )

The Relative Risk compares the cumulative incidence of disease in the exposed group to the cumulative incidence in the unexposed group. R R RR RR is calculated directly in prospective cohort studies and randomized controlled trials (RCTs) where total populations at risk ( a + b a+b a + b and c + d c+d c + d ) are known. R R = Incidence in Exposed Incidence in Unexposed = I e I u = a a + b c c + d RR = \frac{\text{Incidence in Exposed}}{\text{Incidence in Unexposed}} = \frac{I_e}{I_u} = \frac{\frac{a}{a+b}}{\frac{c}{c+d}} RR = Incidence in Unexposed Incidence in Exposed ​ = I u ​ I e ​ ​ = c + d c ​ a + b a ​ ​

Interpretation:

R R = 1.0 RR = 1.0 RR = 1.0 : Null association; exposure does not alter disease risk.

R R > 1.0 RR > 1.0 RR > 1.0 : Exposure is a risk factor, increasing disease probability ( R R = 1.50 ⟹ 50 % RR = 1.50 \implies 50\% RR = 1.50 ⟹ 50% increased risk).

R R < 1.0 RR < 1.0 RR < 1.0 : Exposure is protective ( R R = 0.60 ⟹ 40 % RR = 0.60 \implies 40\% RR = 0.60 ⟹ 40% reduction in disease risk).

2. Odds Ratio ( O R OR OR )

The Odds Ratio is the ratio of the odds of exposure among diseased cases compared to the odds of exposure among non-diseased controls. Because case-control studies select subjects based on disease status rather than exposure, denominators a + b a+b a + b and c + d c+d c + d are arbitrary, rendering direct incidence calculations mathematically invalid. The Odds Ratio serves as the standard measure of association for case-control and cross-sectional studies. Odds of Exposure in Cases = a c , Odds of Exposure in Controls = b d \text{Odds of Exposure in Cases} = \frac{a}{c}, \quad \text{Odds of Exposure in Controls} = \frac{b}{d} Odds of Exposure in Cases = c a ​ , Odds of Exposure in Controls = d b ​ O R = Odds of Exposure in Cases Odds of Exposure in Controls = a c b d = a × d b × c OR = \frac{\text{Odds of Exposure in Cases}}{\text{Odds of Exposure in Controls}} = \frac{\frac{a}{c}}{\frac{b}{d}} = \frac{a \times d}{b \times c} OR = Odds of Exposure in Controls Odds of Exposure in Cases ​ = d b ​ c a ​ ​ = b × c a × d ​

The Rare Disease Assumption ( O R ≈ R R OR \approx RR OR ≈ RR )

When a disease is rare in the underlying population (typically defined as incidence or prevalence < 5 % < 5\% < 5% to 10 % 10\% 10% ): a ≪ b ⟹ a + b ≈ b and c ≪ d ⟹ c + d ≈ d a \ll b \implies a + b \approx b \quad \text{and} \quad c \ll d \implies c + d \approx d a ≪ b ⟹ a + b ≈ b and c ≪ d ⟹ c + d ≈ d

Substituting into the Relative Risk formula: R R = a a + b c c + d ≈ a b c d = a × d b × c = O R RR = \frac{\frac{a}{a+b}}{\frac{c}{c+d}} \approx \frac{\frac{a}{b}}{\frac{c}{d}} = \frac{a \times d}{b \times c} = OR RR = c + d c ​ a + b a ​ ​ ≈ d c ​ b a ​ ​ = b × c a × d ​ = OR

Under the rare disease assumption, the Odds Ratio obtained from a case-control study provides a close mathematical approximation of the true population Relative Risk.

3. Attributable Risk (Risk Difference, A R AR A R / R D RD R D )

Attributable Risk quantifies the absolute excess disease incidence in the exposed cohort directly attributable to the exposure itself, assuming a causal relationship. A R = I e − I u = a a + b − c c + d AR = I_e - I_u = \frac{a}{a+b} - \frac{c}{c+d} A R = I e ​ − I u ​ = a + b a ​ − c + d c ​

Public Health Utility: While R R RR RR measures the biological strength of an association, A R AR A R measures the absolute public health impact—the actual volume of disease that could be prevented if the exposure were eliminated.

4. Attributable Risk Percent ( A R % AR\% A R % / Etiologic Fraction in Exposed)

Attributable Risk Percent represents the proportion of disease occurrences among exposed individuals that is directly attributable to the exposure: A R % = ( I e − I u I e ) × 100 % = ( R R − 1 R R ) × 100 % AR\% = \left( \frac{I_e - I_u}{I_e} \right) \times 100\% = \left( \frac{RR - 1}{RR} \right) \times 100\% A R % = ( I e ​ I e ​ − I u ​ ​ ) × 100% = ( RR RR − 1 ​ ) × 100%

5. Population Attributable Risk ( P A R PAR P A R ) and P A R % PAR\% P A R %

Population Attributable Risk quantifies the excess disease incidence observed in the total community population ( I t I_t I t ​ ) attributable to the risk factor: P A R = I t − I u = p e ( I e − I u ) PAR = I_t - I_u = p_e (I_e - I_u) P A R = I t ​ − I u ​ = p e ​ ( I e ​ − I u ​ ) P A R % = ( I t − I u I t ) × 100 % = ( p e ( R R − 1 ) p e ( R R − 1 ) + 1 ) × 100 % PAR\% = \left( \frac{I_t - I_u}{I_t} \right) \times 100\% = \left( \frac{p_e (RR - 1)}{p_e (RR - 1) + 1} \right) \times 100\% P A R % = ( I t ​ I t ​ − I u ​ ​ ) × 100% = ( p e ​ ( RR − 1 ) + 1 p e ​ ( RR − 1 ) ​ ) × 100%

Where p e p_e p e ​ is the prevalence of the exposure in the total population. P A R % PAR\% P A R % indicates the percentage reduction in overall population disease burden that would occur if the risk factor were completely eradicated.

6. Number Needed to Treat ( N N T NNT NNT ) and Number Needed to Harm ( N N H NNH NN H )

In clinical trials and comparative effectiveness research, binary outcomes are translated into intuitive clinical metrics:

Absolute Risk Reduction ( A R R ARR A RR ): A R R = ∣ I control − I treatment ∣ = ∣ I u − I e ∣ ARR = |I_{\text{control}} - I_{\text{treatment}}| = |I_u - I_e| A RR = ∣ I control ​ − I treatment ​ ∣ = ∣ I u ​ − I e ​ ∣

Relative Risk Reduction ( R R R RRR RRR ): R R R = I u − I e I u = 1 − R R RRR = \frac{I_u - I_e}{I_u} = 1 - RR RRR = I u ​ I u ​ − I e ​ ​ = 1 − RR

Number Needed to Treat ( N N T NNT NNT ):

The average number of patients who must receive the clinical intervention for a specified duration to prevent one additional adverse outcome: N N T = 1 A R R = 1 I u − I e NNT = \frac{1}{ARR} = \frac{1}{I_u - I_e} NNT = A RR 1 ​ = I u ​ − I e ​ 1 ​

Mathematical Rule for NNT: In healthcare analytics, N N T NNT NNT must always be rounded UP to the nearest whole integer (e.g., 16.12 ⟹ 17 16.12 \implies 17 16.12 ⟹ 17 ), because treating 16 patients would fail to prevent the full event.

Absolute Risk Increase ( A R I ARI A R I ) and Number Needed to Harm ( N N H NNH NN H ):

When an intervention increases the risk of an adverse adverse drug reaction or complication: A R I = I treatment − I control = I e − I u ⟹ N N H = 1 A R I = 1 I e − I u ARI = I_{\text{treatment}} - I_{\text{control}} = I_e - I_u \quad \implies \quad NNH = \frac{1}{ARI} = \frac{1}{I_e - I_u} A R I = I treatment ​ − I control ​ = I e ​ − I u ​ ⟹ NN H = A R I 1 ​ = I e ​ − I u ​ 1 ​

N N H NNH NN H represents the number of patients treated before one additional adverse event is caused (rounded down conservatively when assessing safety thresholds).

4. Step-by-Step Worked Calculation: Complete 2x2 Epidemiological Study

Clinical Scenario: A health system analytics department evaluates a 3-year prospective cohort study comparing a novel SGLT2-inhibitor medication regimen against standard metformin monotherapy for preventing Heart Failure Hospitalization among N = 2 , 000 N = 2,000 N = 2 , 000 high-risk diabetic patients.

Exposed Group ( E + E^+ E + , SGLT2-Inhibitor): n 1 = 1 , 000 n_1 = 1,000 n 1 ​ = 1 , 000 patients enrolled; over 3 years, a = 40 a = 40 a = 40 patients were hospitalized for heart failure, and b = 960 b = 960 b = 960 remained unhospitalized.

Unexposed Group ( E − E^- E − , Standard Therapy): n 0 = 1 , 000 n_0 = 1,000 n 0 ​ = 1 , 000 patients enrolled; over 3 years, c = 100 c = 100 c = 100 patients were hospitalized for heart failure, and d = 900 d = 900 d = 900 remained unhospitalized. +-----------------------------------+-----------------------+-----------------------+---------------+

  • | PATIENT COHORT | HOSPITALIZED ($D^+$) | NO EVENT ($D^-$) | TOTAL ENROLLED|
  • +-----------------------------------+-----------------------+-----------------------+---------------+
  • | SGLT2-Inhibitor Regimen ($E^+$) | a = 40 | b = 960 | a + b = 1,000 |
  • | Standard Metformin Regimen ($E^-$)| c = 100 | d = 900 | c + d = 1,000 |
  • +-----------------------------------+-----------------------+-----------------------+---------------+
  • | TOTAL PATIENTS | a + c = 140 | b + d = 1,860 | N = 2,000 |
  • +-----------------------------------+-----------------------+-----------------------+---------------+
  • Step 1: Calculate Cumulative Incidence Rates ( I e I_e I e ​ and I u I_u I u ​ )

Incidence in Exposed ( I e I_e I e ​ ): I e = a a + b = 40 1 , 000 = 0.040 ( 4.0 % I_e = \frac{a}{a+b} = \frac{40}{1,000} = 0.040 \quad (4.0\% I e ​ = a + b a ​ = 1 , 000 40 ​ = 0.040 ( 4.0%

Incidence in Unexposed ( I u I_u I u ​ ): I u = c c + d = 100 1 , 000 = 0.100 ( 10.0 % I_u = \frac{c}{c+d} = \frac{100}{1,000} = 0.100 \quad (10.0\% I u ​ = c + d c ​ = 1 , 000 100 ​ = 0.100 ( 10.0%

Step 2: Compute the Relative Risk ( R R RR RR ) R R = I e I u = 0.040 0.100 = 0.40 RR = \frac{I_e}{I_u} = \frac{0.040}{0.100} = \mathbf{0.40} RR = I u ​ I e ​ ​ = 0.100 0.040 ​ = 0.40

Interpretation: Patients receiving the SGLT2-inhibitor regimen have 0.40 0.40 0.40 times the risk of 3-year heart failure hospitalization compared to those receiving standard therapy.

Step 3: Compute the Odds Ratio ( O R OR OR ) O R = a × d b × c = 40 × 900 960 × 100 = 36 , 000 96 , 000 = 0.375 OR = \frac{a \times d}{b \times c} = \frac{40 \times 900}{960 \times 100} = \frac{36,000}{96,000} = \mathbf{0.375} OR = b × c a × d ​ = 960 × 100 40 × 900 ​ = 96 , 000 36 , 000 ​ = 0.375

Interpretation: The odds of hospitalization among SGLT2i recipients are 0.375 0.375 0.375 times the odds among standard therapy patients. Notice that because baseline hospitalization risk is moderately low (10%), O R = 0.375 OR = 0.375 OR = 0.375 closely tracks R R = 0.400 RR = 0.400 RR = 0.400 .

Step 4: Compute the Absolute Risk Reduction ( A R R ARR A RR ) & Relative Risk Reduction ( R R R RRR RRR )

A R R = I u − I e = 0.100 − 0.040 = 0.060 ( 6.0 % ARR = I_u - I_e = 0.100 - 0.040 = 0.060 \quad (6.0\% A RR = I u ​ − I e ​ = 0.100 − 0.040 = 0.060 ( 6.0%

R R R = 1 − R R = 1 − 0.40 = 0.600 ( 60.0 % RRR = 1 - RR = 1 - 0.40 = 0.600 \quad (60.0\% RRR = 1 − RR = 1 − 0.40 = 0.600 ( 60.0% Interpretation: The medication yields an absolute risk reduction of 6.0 percentage points and a relative risk reduction of 60.0%.

Step 5: Compute the Number Needed to Treat ( N N T NNT NNT ) N N T = 1 A R R = 1 0.060 = 16.6667 ⟹ 17 patients NNT = \frac{1}{ARR} = \frac{1}{0.060} = 16.6667 \implies \mathbf{17 \text{ patients}} NNT = A RR 1 ​ = 0.060 1 ​ = 16.6667 ⟹ 17 patients

Interpretation: Treating about 17 similar high-risk patients for 3 years is associated with one fewer heart-failure hospitalization on average, assuming the trial effect transports to the target population.

5. Master Summary of Epidemiological Formulas

Epidemiological Concept Standard Formula Primary Analytic Setting Practical Clinical / Health Plan Use

Point Prevalence Existing Cases at t 0 Population at t 0 \frac{\text{Existing Cases at } t_0}{\text{Population at } t_0} Population at t 0 ​ Existing Cases at t 0 ​ ​ Cross-Sectional Studies, Claims snapshots Chronic disease registry sizing; capitation budget setting

Cumulative Incidence ( C I CI C I ) New Cases in Period Disease-Free Population at Start \frac{\text{New Cases in Period}}{\text{Disease-Free Population at Start}} Disease-Free Population at Start New Cases in Period ​ Closed Prospective Cohorts, Fixed Trials 5-year post-operative complication risk; vaccine efficacy

Incidence Rate ( I R IR I R ) New Cases in Period ∑ Person-Time at Risk \frac{\text{New Cases in Period}}{\sum \text{Person-Time at Risk}} ∑ Person-Time at Risk New Cases in Period ​ Dynamic Cohorts, Registries, EHR Data Infection density per 1,000 catheter days; disease rate

Relative Risk ( R R RR RR ) I e I u = a / ( a + b ) c / ( c + d ) \frac{I_e}{I_u} = \frac{a / (a+b)}{c / (c+d)} I u ​ I e ​ ​ = c / ( c + d ) a / ( a + b ) ​ Prospective Cohorts, RCTs Assessing drug efficacy, surgical safety, etiology

Odds Ratio ( O R OR OR ) a × d b × c \frac{a \times d}{b \times c} b × c a × d ​ Case-Control Studies, Cross-Sectional Retrospective risk factor discovery; logistic regression

Attributable Risk ( A R AR A R ) I e − I u I_e - I_u I e ​ − I u ​ Cohort Studies, Public Health Quantifying absolute caseload attributable to exposure

Attributable Risk % ( A R % AR\% A R % ) I e − I u I e = R R − 1 R R \frac{I_e - I_u}{I_e} = \frac{RR-1}{RR} I e ​ I e ​ − I u ​ ​ = RR RR − 1 ​ Etiology Studies, Health Economics Fraction of disease in exposed prevented by intervention

Number Needed to Treat ( N N T NNT NNT ) 1 I u − I e = 1 A R R \frac{1}{I_u - I_e} = \frac{1}{ARR} I u ​ − I e ​ 1 ​ = A RR 1 ​ RCTs, Comparative Effectiveness Clinical utility benchmarking; formulary inclusion decisions

Case Fatality Rate ( C F R CFR CFR ) Deaths from Disease Diagnosed Disease Cases \frac{\text{Deaths from Disease}}{\text{Diagnosed Disease Cases}} Diagnosed Disease Cases Deaths from Disease ​ Inpatient Outbreaks, Oncology Registries Evaluating disease virulence and acute clinical severity

Standardized Infection Ratio ( S I R SIR S I R ) Observed HAIs Predicted HAIs \frac{\text{Observed HAIs}}{\text{Predicted HAIs}} Predicted HAIs Observed HAIs ​ CDC NHSN, CMS Hospital HAC Reporting Value-based purchasing quality adjustments & penalties

Loading diagram... Epidemiological Measures Selection Architecture